| Boehringer Ingelheim reports 'significant benefits' of Actilyse | Posted on 26/09/2008 in Pharmaceutical Company Product News Boehringer Ingelheim has announced the results of new research showing the benefits of Actilyse (alteplase) in patients with acute ischaemic stroke beyond the three-hour treatment window currently approved by regulators.
The results from the European Cooperative Acute Stroke Study were presented at the World Stroke Congress held in Vienna, Austria and published in the New England Journal of Medicine.
Boehringer Ingelheim said the safety profile of the recombinant tissue plasminogen activator when used in the three to four-and-a-half time window is consistent with that reported in previous trials for zero to three hours.
This safety profile includes the incidence of haemorrhagic events.
Professor Werner Hacke of the Department of Neurology at Ruprecht-Karls-University of Heidelberg, Germany, said: "The results of the trial show that a large group of patients currently excluded may benefit in the future from this therapy."
He added while early treatment is the foundation of therapy for acute stroke treatments, the new study data shows stroke can also be effectively managed in patients unable to reach a stroke centre within three hours.
Earlier this week, Boehringer Ingelheim and Pfizer released the results of a new analysis of trials showing the long-term safety profile of Spiriva (tiotropium).Other news stories from 26/09/2008
Read more in the Zenopa News Archive
How this news is generated
|  |
|
